Illumina (($ILMN)) has held its Q3 earnings call. Read on for the main highlights of the call. Illumina’s recent earnings call painted a picture ...

Having examined the options trading patterns of Illumina, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance Trading volume ...

Illumina continues to focus on transforming human health practices through its leadership of genomic sequencing and related applications. The firm provides a broad range of instruments and related ...

Illumina’s revenue was flat for the third quarter as the sequencing giant continues to deal with headwinds from a China sales ...

Discover key Q3 2025 earnings insights for Illumina, including raised outlook, NovaSeq X growth, and margin expansion.

Illumina (ILMN) reported $1.08 billion in revenue for the quarter ended September 2025, representing a year-over-year increase of 0.4%. EPS of $1.34 for the same period compares to $1.14 a year ...

Genomics has administered a double dose of litigation to Illumina, joining with separate partners in a pair of federal lawsuits accusing the sequencing giant of infringing on nine patents related to ...

Sunday's editorial cartoons include Pete Hegseth and the press, an absence of government, and more From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered ...

This week, the Broad Institute gene-sequencing lab said it read infants’ DNA genomes in less than four hours, cutting an hour off the previous Guinness World Record. The point for investors is that ...

Earlier this year, the U.S. Department of Justice (DOJ) announced Illumina Inc. agreed to pay $9.8 million to resolve allegations under the False Claims Act (FCA) relating to cybersecurity ...

Taiwan-based gene sequencing company Genomics BioSci & Tech has entered a strategic partnership with global sequencing leader Illumina to jointly promote gene sequencing and multi-omics technologies ...